drugset
drugset / Trial / NCT04718727

Olanzapine for the Prevention of Postoperative Nausea and Vomiting

NCT04718727 ↗

Phase 1/2 Completed 132 enrolled Amani Hassan Abdel-Wahab
RandomizedParallel-groupQuadruple-blindPrevention

Summary

Nausea and vomiting (PONV) remain a common problem in surgical units. Even after two or three prophylactic antiemetic interventions, patients with all four of the Apfel risk factors for PONV have an estimated 30 to 40% chance of suffering PONV. Olanzapine as an antiemetic represents a new use of an antipsychotic drug.

Timeline

Start
2021-03-15
Primary completion
2023-02-01
Completion
2023-02-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Olanzapine Small molecule 5 mg Oral
Comparator Olanzapine Small molecule 10 mg Oral

Indications

No indication recorded.